Rodolphe Jantzen

Rodolphe Jantzen

Auto-generated profile, based on publicly available information

Rodolphe Jantzen

CARTaGENE, Research Center, CHU Sainte-Justine, Montreal, QC, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
GRGregory Rembeyo
Gregory Rembeyo
JCJean-Michel Correas
Jean-Michel Correas
RJRodolphe Jantzen
Rodolphe Jantzen
FAFrançois Audenet
François Audenet
CDCharles Dariane
Charles Dariane
MTMarc-Olivier Timsit
Marc-Olivier Timsit

18 March 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
RJRodolphe Jantzen
Rodolphe Jantzen
MMMathieu Maltais
Mathieu Maltais
PBPhilippe Broët
Philippe Broët
Introduction: The objective of this study was to characterize the combinations of demographic and socioeconomic characteristics associated to the unwillingness to receive the COVID-19 vaccines during the 2021 Quebec's vaccination campaign.Materials and Methods: In March-June 2021, we conducted an online survey of the participants of the CARTaGENE population-based cohort, composed of middle-aged and older adults. After comparing the vaccinated and unvaccinated participants, we investigated vaccine hesitancy among participants who were unvaccinated. For identifying homogeneous groups of individuals with respect to vaccine hesitancy, we used a machine learning approach based on a hybrid tree-based model.Results: Among the 6,105 participants of the vaccine cohort, 3,553 (58.2%) had at least one dose of COVID-19 vaccine. Among the 2,552 participants, 221 (8.7%) did not want to be vaccinated (91) or were uncertain (130). The median age for the unvaccinated participants was 59.3 years [IQR 54.7–63.9]. The optimal hybrid tree-based model identified seven groups. Individuals having a household income lower than $100,000 and being born outside of Canada had the highest rate of vaccine hesitancy (28% [95% CI 19.8–36.3]). For those born in Canada, the vaccine hesitancy rate among the individuals who have a household income below $50,000 before the pandemic or are Non-retired was of 12.1% [95% CI 8.7–15.5] and 10.6% [95% CI 7.6–13.7], respectively. For the participants with a high household income before the pandemic (more than $100,000) and a low level of education, those who experienced a loss of income during the pandemic had a high level of hesitancy (19.2% [8.5–29.9]) whereas others who did not experience a loss of income had a lower level of hesitancy (6.0% [2.8–9.2]). For the other groups, the level of hesitancy was low of around 3% (3.2% [95% CI 1.9–4.4] and 3.4% [95% CI 1.5–5.2]).Discussion: Public health initiatives to tackle vaccine hesitancy should take into account these socio-economic determinants and deliver personalized messages toward people having socio-economic difficulties and/or being part of socio-cultural minorities.

3 April 2018 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
ILIvan Lerner
Ivan Lerner
RVRaphael Veil
Raphael Veil
DNDinh-Phong Nguyen
Dinh-Phong Nguyen
VLVinh Phuc Luu
Vinh Phuc Luu
RJRodolphe Jantzen
Rodolphe Jantzen
Revolution in Health Care: How Will Data Science Impact Doctor–Patient Relationships?

1 March 2023 in CMAJ Open
Verified
Journal Article
Open access
PDF file
RJRodolphe Jantzen
Rodolphe Jantzen
NENicole Ezer
Nicole Ezer
SCSophie Camilleri-Broët
Sophie Camilleri-Broët
MTMartin C. Tammemägi
Martin C. Tammemägi
PBPhilippe Broët
Philippe Broët
Background: The PLCOm2012 prediction tool for risk of lung cancer has been proposed for a pilot program for lung cancer screening in Quebec, but has not been validated in this population. We sought to validate PLCOm2012 in a cohort of Quebec residents, and to determine the hypothetical performance of different screening strategies. Methods: We included smokers without a history of lung cancer from the population-based CARTaGENE cohort. To assess PLCOm2012 calibration and discrimination, we determined the ratio of expected to observed number of cases, as well as the sensitivity, specificity and positive predictive values of different risk thresholds. To assess the performance of screening strategies if applied between Jan. 1, 1998, and Dec. 31, 2015, we tested different thresholds of the PLCOm2012 detection of lung cancer over 6 years (1.51%, 1.70% and 2.00%), the criteria of Quebec’s pilot program (for people aged 55–74 yr and 50–74 yr) and recommendations from 2021 United States and 2016 Canada guidelines. We assessed shift and serial scenarios of screening, whereby eligibility was assessed annually or every 6 years, respectively. Results: Among 11 652 participants, 176 (1.51%) lung cancers were diagnosed in 6 years. The PLCOm2012 tool underestimated the number of cases (expected-to-observed ratio 0.68, 95% confidence interval [CI] 0.59–0.79), but the discrimination was good (C-statistic 0.727, 95% CI 0.679–0.770). From a threshold of 1.51% to 2.00%, sensitivities ranged from 52.3% (95% CI 44.6%–59.8%) to 44.9% (95% CI 37.4%–52.6%), specificities ranged from 81.6% (95% CI 80.8%–82.3%) to 87.7% (95% CI 87.0%–88.3%) and positive predictive values ranged from 4.2% (95% CI 3.4%–5.1%) to 5.3% (95% CI 4.2%–6.5%). Overall, 8938 participants had sufficient data to test performance of screening strategies. If eligibility was estimated annually, Quebec pilot criteria would have detected fewer cancers than PLCOm2012 at a 2.00% threshold (48.3% v. 50.2%) for a similar number of scans per detected cancer. If eligibility was estimated every 6 years, up to 26 fewer lung cancers would have been detected; however, this scenario led to higher positive predictive values (highest for PLCOm2012 with a 2.00% threshold at 6.0%, 95% CI 4.8%–7.3%). Interpretation: In a cohort of Quebec smokers, the PLCOm2012 risk prediction tool had good discrimination in detecting lung cancer, but it may be helpful to adjust the intercept to improve calibration. The implementation of risk prediction models in some of the provinces of Canada should be done with caution.

16 March 2020 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
Thomas RobertThomas Robert
Thomas Robert
RJRodolphe Jantzen
Rodolphe Jantzen
ACAlexandra Cambier
Alexandra Cambier
MJMatthieu Jamme
Matthieu Jamme
CCCécile Couchoud
Cécile Couchoud
TRThe Rein Registry
The Rein Registry
Background: Although end-stage renal disease (ESRD) is frequently used as an outcome marker for primary immunoglobulin A nephropathy (IgAN), the clinical course after reaching ESRD is not well documented. This study examined patients’ characteristics and survival in ESRD-related biopsy-proven IgAN in France. Methods: French Renal Epidemiology and Information Network Registry data from 2010 to 2014 were used to analyse patients’ survival and outcome in incident ESRD patients >16 years of age with biopsy-proven primary IgAN, in comparison with other primary and secondary glomerulonephritis (GN), adult polycystic kidney disease (ADPKD) or diabetes. Multivariable survival analysis was adjusted for age, sex, time on dialysis and comorbidities. Results: Among 17 138 incident dialysis patients with ESRD, IgAN (242.8/10 000 dialysis initiation) represents the most common GN related to ESRD during 2010. IgAN patients were the youngest, and had the fewest comorbidities and the highest use of peritoneal dialysis (PD) (17%). In comparison with the haemodialysis group, hazard ratios for death were not different in the preemptive transplantation group [0.46, 95% confidence interval (CI) 0.17–1.28] and in the PD group (0.77, 95% CI 0.44–1.33). Mortality rates in IgAN patients with preemptive transplantation and in those receiving dialysis waiting for transplantation were 2.9% (95% CI 0.0–5.6) and 6.7% (95% CI 0.9–12.3). Mortality rates of ADPKD patients receiving dialysis waiting for transplantation were higher (18%, 95% CI 3.1–30.6). Conclusion: IgAN has the best prognosis among primary and secondary GN. IgAN patients receiving dialysis waiting transplantation seem to have a more favourable prognosis than ADPKD patients, who usually comprise the reference population. The underlying reasons for the difference in access treatment modalities should be investigated to improve survival with respect to renal disease.

12 April 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
RJRodolphe Jantzen
Rodolphe Jantzen
YPYves Payette
Yves Payette
TMThibault de Malliard
Thibault de Malliard
CLCatherine Labbé
Catherine Labbé
NNNolwenn Noisel
Nolwenn Noisel
PBPhilippe Broët
Philippe Broët
Objectives Evaluate the accuracy of the Breast Cancer Risk Assessment Tool (BCRAT), International Breast Cancer Intervention Study risk evaluation tool (IBIS), Polygenic Risk Scores (PRS) and combined scores (BCRAT+PRS and IBIS +PRS) to predict the occurrence of invasive breast cancers at 5 years in a French-Canadian population. Design Population-based cohort study. Setting We used the population-based cohort CARTaGENE, composed of 43 037 Quebec residents aged between 40 and 69 years and broadly representative of the population recorded on the Quebec administrative health insurance registries. Participants 10 200 women recruited in 2009–2010 were included for validating BCRAT and IBIS and 4555 with genetic information for validating the PRS and combined scores. Outcome measures We computed the absolute risks of breast cancer at 5 years using BCRAT, IBIS, four published PRS and combined models. We reported the overall calibration performance, goodness-of-fit test and discriminatory accuracy. Results 131 (1.28%) women developed a breast cancer at 5 years for validating BCRAT and IBIS and 58 (1.27%) for validating PRS and combined scores. Median follow-up was 5 years. BCRAT and IBIS had an overall expected-to-observed ratio of 1.01 (0.85–1.19) and 1.02 (0.86–1.21) but with significant differences when partitioning by risk groups (p<0.05). IBIS’ c-index was significantly higher than BCRAT (63.42 (59.35–67.49) vs 58.63 (54.05–63.21), p=0.013). PRS scores had a global calibration around 0.82, with a CI including one, and non-significant goodness-of-fit tests. PRS’ c-indexes were non-significantly higher than BCRAT and IBIS, the highest being 64.43 (58.23–70.63). Combined models did not improve the results. Conclusions In this French-Canadian population-based cohort, BCRAT and IBIS have good mean calibration that could be improved for risk subgroups, and modest discriminatory accuracy. Despite this modest discriminatory power, these tools can be of interest for primary care physicians for delivering a personalised message to their high-risk patients, regarding screening and lifestyle counselling.